

US Patent & Trademark Office

Patent Public Search | Text View

United States Patent	12384824
Kind Code	B2
Date of Patent	August 12, 2025
Inventor(s)	Shimizu; Masashi et al.

Method for producing an active hepatocyte growth factor (HGF)

Abstract

The present invention provides a method for producing active hepatocyte growth factor activator (HGFA) and active hepatocyte growth factor (HGF) without using animal serum. The present invention relates to a method for producing active HGFA without using animal serum. The method is characterized in that it comprises a step of obtaining a culture supernatant comprising pro-HGFA by culturing mammalian cells expressing inactive hepatocyte growth factor activator (pro-HGFA) in a medium without serum, and a step of adjusting the culture supernatant comprising pro-HGFA obtained in the above step to weakly acidic to convert pro-HGFA into active HGFA. The present invention also relates to a method for producing active HGF with HGFA produced by said method.

Inventors: Shimizu; Masashi (Tsukuba, JP), Sato; Toshitaka (Kobe, JP), Arita; Yoshihisa (Kobe, JP)

Applicant: Eisai R&D Management Co., Ltd. (Tokyo, JP)

Family ID: 59850449

Assignee: Eisai R&D Management Co., Ltd. (Tokyo, JP)

Appl. No.: 18/429738

Filed: February 01, 2024

Prior Publication Data

Document Identifier	Publication Date
US 20240218035 A1	Jul. 04, 2024

Foreign Application Priority Data

JP	2016-054128	Mar. 17, 2016
----	-------------	---------------

Related U.S. Application Data

Publication Classification

Int. Cl.: **C07K14/475** (20060101); **C12N5/10** (20060101); **C12N9/64** (20060101); **C12N15/09** (20060101); **C12P21/02** (20060101)

U.S. Cl.:

CPC **C07K14/4753** (20130101); **C12N9/64** (20130101); **C12P21/02** (20130101); C12N5/10 (20130101); C12N15/09 (20130101)

Field of Classification Search

USPC: None

References Cited

U.S. PATENT DOCUMENTS

Patent No.	Issued Date	Patentee Name	U.S. Cl.	CPC
5004805	12/1990	Gohda et al.	N/A	N/A
5466593	12/1994	Shimomura et al.	N/A	N/A
5587359	12/1995	Higashio et al.	N/A	N/A
5677164	12/1996	Shimomura et al.	N/A	N/A
5804557	12/1997	Cleland et al.	N/A	N/A
6699837	12/2003	Nakamura	N/A	N/A
7741096	12/2009	Eigenbrot, Jr. et al.	N/A	N/A
8759491	12/2013	Ganesan et al.	N/A	N/A
9670275	12/2016	Kolkman et al.	N/A	N/A
2001/0051604	12/2000	Tanaka et al.	N/A	N/A
2005/0220758	12/2004	Zobel et al.	N/A	N/A
2009/0233863	12/2008	Adachi et al.	N/A	N/A
2010/0137213	12/2009	Fernandez et al.	N/A	N/A
2013/0071931	12/2012	Ishikawa	N/A	N/A
2013/0142792	12/2012	Rothlein et al.	N/A	N/A
2014/0234341	12/2013	Tsubouchi et al.	N/A	N/A
2017/0189487	12/2016	Ohori et al.	N/A	N/A
2019/0062390	12/2018	Shimizu et al.	N/A	N/A
2020/0341014	12/2019	Kimura et al.	N/A	N/A
2022/0267393	12/2021	Shimizu et al.	N/A	N/A

FOREIGN PATENT DOCUMENTS

Patent No.	Application Date	Country	CPC
2017232582	12/2016	AU	N/A
1367703	12/2001	CN	N/A
102271707	12/2010	CN	N/A
0596524	12/1993	EP	N/A

1180368	12/2001	EP	N/A
S63-22526	12/1987	JP	N/A
H03-285693	12/1990	JP	N/A
H04-030000	12/1991	JP	N/A
H05-103670	12/1992	JP	N/A
H5-103670	12/1992	JP	N/A
H05-111383	12/1992	JP	N/A
H06-153966	12/1993	JP	N/A
H6-153966	12/1993	JP	N/A
2577091	12/1996	JP	N/A
H09-025241	12/1996	JP	N/A
2747979	12/1997	JP	N/A
H10-167982	12/1997	JP	N/A
2859577	12/1998	JP	N/A
H11-056382	12/1998	JP	N/A
3072628	12/1999	JP	N/A
3213985	12/2000	JP	N/A
2002-356500	12/2001	JP	N/A
2010-513462	12/2009	JP	N/A
2012-051822	12/2011	JP	N/A
2012-507553	12/2011	JP	N/A
2013-520166	12/2012	JP	N/A
10-2002-0064141	12/2001	KR	N/A
2113480	12/1997	RU	N/A
2316348	12/2007	RU	N/A
2506946	12/2013	RU	N/A
201141507	12/2010	TW	N/A
WO 1990/010651	12/1989	WO	N/A
WO 2000/072873	12/1999	WO	N/A
WO 2006/014928	12/2005	WO	N/A
WO 2007/122975	12/2006	WO	N/A
WO 2008/078189	12/2007	WO	N/A
WO 2008/102849	12/2007	WO	N/A
WO 2011/049868	12/2010	WO	N/A
WO 2012/144535	12/2011	WO	N/A
WO 2014/063128	12/2013	WO	N/A

OTHER PUBLICATIONS

Acceptance Fee Receipt in Australian Patent Application No. 2015254307, dated Dec. 9, 2019, 1 page. cited by applicant

Amendment and Response filed in Russian Patent Application No. 2016146121, dated Apr. 9, 2019, 11 pages (with English Translation). cited by applicant

Amendment and Response to Japanese Office Action in Japanese Patent Application No. 2016-516354, dated Feb. 7, 2019, 11 pages (with English Translation). cited by applicant

Amendment filed in Japanese Patent Application No. 2016-516354, dated Feb. 7, 2019, 3 pages (with English Translation). cited by applicant

Apalikova et al., "Sorbing Polymers Based on Iron Oxyhydrates," Bulletin of Chelyabinsk Scientific Center, South Ural State University, Chelyabinsk, Russia, Aug. 2000, vol. 3, UDC:546.723-36 (with English Translation). cited by applicant

Arshinova et al., "Excipients in technology of lyophilization of drug preparations," Scientific and

Manufacturing Journal—Development and Registration of Medicaments, 2013, p. 20-25 (with English Translation). cited by applicant

Cell Signaling Technology [Online], “ApoA4 (1D6B6) Mouse mAb,” Feb. 2016, [Retrieved on Sep. 10, 2019], retrieved from: URL<<https://media.cellsignal.com/pdf/5700.pdf>>, 1 page. cited by applicant

Certificate of Patent and Notification of Grant in Singaporean Patent Application No. 10201809228R, dated Oct. 8, 2021, 3 pages. cited by applicant

Certificate of Patent for Israeli Patent No. 248377, granted on Jul. 31, 2020, 2 pages. cited by applicant

Certificate of Patent in Australian Patent No. 2015254307, granted on Feb. 20, 2020, 1 page. cited by applicant

Certificate of Patent in Chinese Patent No. ZL 2017800130577, announced on Jan. 11, 2022, 4 pages (with English Translation). cited by applicant

Certificate of Patent in Israeli Patent No. 261066, granted on Dec. 1, 2021, 2 pages (with English Translation). cited by applicant

Certificate of Patent in Japanese Patent No. 6568846, granted on Aug. 9, 2019, 2 pages (with English Translation). cited by applicant

Certificate of Patent in Russian Patent No. 2693472, granted on Jul. 3, 2019, 66 pages (with English Translation). cited by applicant

Certificate of Patent in Singaporean Patent No. 11201806843U, granted on Apr. 13, 2022, 1 page. cited by applicant

Certificate of Patent in Taiwanese Patent No. 1674902, granted on Oct. 21, 2019, 2 pages (with English Translation). cited by applicant

Chapanian R. et al., “Combined and sequential delivery of bioactive VEGF165 and HGF from poly(trimethylene carbonate) based photo-crosslinked elastomers,” Journal of Controlled Release, 2010, vol. 143, p. 53-63. cited by applicant

Communication pursuant to Article 94(3) EPC in European Patent Application No. 17766767.2, dated Apr. 6, 2021, 5 pages. cited by applicant

Communication pursuant to Article 94(3) EPC in European Patent Application No. 17766767.2, dated Jun. 23, 2020, 6 pages. cited by applicant

Communication under Rule 71(3) EPC in European Patent Application No. 15786509.8, dated Feb. 16, 2021, 69 pages. cited by applicant

Communication under Rule 71(3) EPC in European Patent Application No. 17766718.5, dated Apr. 28, 2021, 51 pages. cited by applicant

Corrected Notice of Allowability in U.S. Appl. No. 15/305,049, dated Jan. 27, 2020, 7 pages. cited by applicant

Corrected Notice of Allowability in U.S. Appl. No. 15/305,049, dated Mar. 5, 2020, 7 pages. cited by applicant

Decision of Grant for Japanese Patent Application No. 2016-516354, dated Jul. 24, 2019, 4 pages (with English Translation). cited by applicant

Decision of Grant for Russian Patent Application No. 2016146121, dated Apr. 25, 2019, 12 pages, (with English Translation). cited by applicant

Decision of Grant for Russian Patent Application No. 2018130530, dated Apr. 7, 2021, 14 pages (with English Translation). cited by applicant

Decision of Grant for Russian Patent Application No. 2019119586, dated Jun. 22, 2022, 15 pages (with English Translation). cited by applicant

European Extended Search Report in European Patent Application No. 17766718.5, dated Oct. 22, 2019, 5 pages. cited by applicant

European Extended Search Report in European Patent Application No. 17766767.2, dated Sep. 19, 2019, 7 pages. cited by applicant

Gohda et al., "Purification and partial characterization of hepatocyte growth factor from plasma of a patient with fulminant hepatic failure," *The Journal of Clinical Investigation*, (1988), 81(2):414-419. cited by applicant

Hüpeden et al., "Relative abundance of *Nitrotoga* spp. in a biofilter of a cold-freshwater aquaculture plant appears to be stimulated by slightly acidic pH," *Applied and Environmental Microbiology*, Mar. 2016, 82(6):1838-1845. cited by applicant

IN Official Communication of the Intimation of Grant and Patent Certificate of Indian Patent No. 371199 in Indian Appln. No. 201647036821, dated Jul. 6, 2021, 2 pages (with English Translation). cited by applicant

International Preliminary Report on Patentability in International Application No. PCT/JP2015/062523, dated Nov. 1, 2016, 4 pages. cited by applicant

International Search Report for International Patent Application No. PCT/JP2015/062523 dated Jul. 28, 2015, 6 pages (with English Translation). cited by applicant

International Search Report in International Application No. PCT/JP2017/010355, dated May 30, 2017, 4 pages (with English Translation). cited by applicant

International Search Report in International Application No. PCT/JP2017/010587, dated May 23, 2017, 4 pages (with English Translation). cited by applicant

Kaibori et al., "Hepatocyte Growth Factor Stimulates Synthesis of Lipids and Secretion of Lipoproteins in Rat Hepatocytes," *Hepatology*, (1998), 27(5)1354-1361. cited by applicant

Kamimoto et al., "Hepatocyte growth factor prevents multiple organ injuries in endotoxemic mice through a heme oxygenase-1-dependent mechanism," *Biochemical and Biophysical Research Communications*, 2009, 380:333-337. cited by applicant

Kataoka et al., "Hepatocyte growth factor activator (HGFA): pathophysiological functions in vivo," Minireview, *The FEBS Journal*, 2010, 277(10):2230-2237. cited by applicant

Kirchhofer et al., "Tissue Expression, Protease Specificity, and Kunitz Domain Functions of Hepatocyte Growth Factor Activator Inhibitor-1B (HAI-1B), a New Splice Variant of HAI-1," *The Journal of Biological Chemistry*, Jun. 18, 2003, 278(38):36341-36349. cited by applicant

Kosone et al., "HGF ameliorates a high-fat diet-induced fatty liver," *American Journal of Physiology—Gastrointestinal and Liver Physiology*, (2007), 293(1):G204-G210. cited by applicant

Letter Patent granted in Australian Patent No. 2017232582, dated Oct. 27, 2022, 1 page. cited by applicant

Letter Patent granted in Canadian Patent No. 2947396, dated Oct. 19, 2021, 61 pages. cited by applicant

Letter Patent granted in European Patent No. 3138575, dated Jul. 14, 2021, 2 pages. cited by applicant

Letter Patent granted in Korean Patent No. 10-2291913, dated Aug. 13, 2021, 3 pages (with English Translation). cited by applicant

Letter Patent granted in Mexican Patent No. 372156, dated Mar. 11, 2021, 106 pages (with English Translation). cited by applicant

Letter Patent granted in Mexican Patent No. 395311, dated Sep. 5, 2022, 60 pages (with Cover Page Translation). cited by applicant

Letter Patent granted in Russian Patent No. 2776108, dated Jul. 13, 2022, 5 pages, (with Cover Page Translation). cited by applicant

Letter Patent granted in Taiwanese Patent No. I728409, dated May 21, 2021, 2 pages (with English Translation). cited by applicant

Martoglio et al., *Trends in Cell Biology*, 8:410-415, 1998. cited by applicant

Miyazawa et al., *Journal of Biological Chemistry*, vol. 268, No. 14, Issue of May 15, pp. 10024-10028, 1993. cited by applicant

Mukai et al., "Activation of hepatocyte growth factor activator zymogen (pro-HGFA) by human kallikrein 1-related peptidases," *The FEBS Journal*, 2008, 275:1003-1017. cited by applicant

Nakamura et al., "Hepatocyte growth factor twenty years on: Much more than a growth factor," Journal of Gastroenterology and Hepatology, (2011), 26(S1):188-202. cited by applicant

Nakamura et al., "Molecular cloning and expression of human hepatocyte growth factor", Nature, 1989, vol. 342, p. 440-443. cited by applicant

NCBI Accession No. 004756, downloaded Aug. 31, 2023. cited by applicant

Notice of Acceptance in Australian Patent Application No. 2015254307, dated Oct. 24, 2019, 3 pages. cited by applicant

Notice of Acceptance in Australian Patent Application No. 2017232582, dated Jun. 29, 2022, 3 pages. cited by applicant

Notice of Allowance in Canadian Patent Application No. 2947396, dated Jul. 23, 2021, 1 page (with English Translation). cited by applicant

Notice of Allowance in Canadian Patent Application No. 3,014,567, dated Dec. 8, 2023, 1 page. cited by applicant

Notice of Allowance in Chinese Patent Application No. 201580021294.9, dated Sep. 19, 2019, 3 pages (with English Translation). cited by applicant

Notice of Allowance in Israeli Patent Application No. 248377, dated Jan. 15, 2020, 8 pages (with English Translation). cited by applicant

Notice of Allowance in Israeli Patent Application No. 261066, dated Jun. 7, 2021, 7 pages (with English Translation). cited by applicant

Notice of Allowance in Japanese Patent Application No. 2018-505972, dated Mar. 22, 2021, 6 pages (with English Translation). cited by applicant

Notice of Allowance in Korean Patent Application No. 10-2016-7029770, dated Jul. 28, 2021, 3 pages (with English Translation). cited by applicant

Notice of Allowance in Mexican Patent Application No. MX/a/2016/013667, dated Feb. 4, 2020, 5 pages (with English Translation). cited by applicant

Notice of Allowance in Mexican Patent Application No. MX/a/2018/010283, dated Jul. 5, 2022, 4 pages (with English Translation). cited by applicant

Notice of Allowance in Taiwanese Patent Application No. 104113328, dated Jun. 13, 2019, 5 pages (with English Translation). cited by applicant

Notice of Allowance in Taiwanese Patent Application No. 108125333, dated Mar. 11, 2021, 7 pages (with English Translation). cited by applicant

Notice of Allowance in U.S. Appl. No. 15/305,049, dated Apr. 30, 2021, 7 pages. cited by applicant

Notice of Allowance in U.S. Appl. No. 15/305,049, dated Dec. 27, 2018, 10 pages. cited by applicant

Notice of Allowance in U.S. Appl. No. 15/305,049, dated Jul. 27, 2021, 12 pages. cited by applicant

Notice of Allowance in U.S. Appl. No. 15/305,049, dated May 18, 2020, 11 pages. cited by applicant

Notice of Allowance in U.S. Appl. No. 15/305,049, dated Oct. 14, 2020, 9 pages. cited by applicant

Notice of Allowance in U.S. Appl. No. 15/305,049, dated Sep. 17, 2019, 14 pages. cited by applicant

Notice of Eligibility for Grant and Supplementary Examination Report in Singaporean Patent Application No. 10201809228R, dated Sep. 7, 2021, 4 pages. cited by applicant

Notice of Eligibility for Grant and Support Therefor in Singaporean Patent Application No. 11201806843U, dated Jan. 12, 2022, 4 pages. cited by applicant

Notice to Grant a Patent for Invention in Chinese Patent Application No. 201780013057.7, dated Dec. 17, 2021, 2 pages (with English Translation). cited by applicant

Notification of Grant in Singaporean Patent Application No. 11201806843U, dated Apr. 13, 2022, 2 pages. cited by applicant

Notification of Patent Registration in Chinese Patent Application No. 201780013057.7, dated Dec.

17, 2021, 2 pages (with English Translation). cited by applicant
Office Action and Search Report in Chinese Patent Application No. 201580021294.9, dated Mar. 27, 2019, 12 pages (with English Translation). cited by applicant
Office Action and Search Report in Chinese Patent Application No. 201780013057.7, dated Aug. 10, 2021, 15 pages (with English Translation). cited by applicant
Office Action in Australian Patent Application No. 2015254307, dated Jun. 25, 2019, 3 pages. cited by applicant
Office Action in Australian Patent Application No. 2015254307, dated Oct. 10, 2019, 3 pages. cited by applicant
Office Action in Australian Patent Application No. 2017232582, dated May 30, 2022, 3 pages. cited by applicant
Office Action in Brazilian Patent Application No. 112016025051-6, dated Oct. 4, 2023, 9 pages (with English Translation). cited by applicant
Office Action in Canadian Patent Application No. 2947396, dated Dec. 23, 2020, 4 pages. cited by applicant
Office Action in Canadian Patent Application No. 3014567, dated Feb. 15, 2023, 4 pages. cited by applicant
Office Action in Indian Patent Application No. 201647036821, dated Nov. 27, 2019, 6 pages. cited by applicant
Office Action in Indian Patent Application No. 201847031049, dated Oct. 19, 2020, 6 pages. cited by applicant
Office Action in Israeli Patent Application No. 248377, dated Nov. 12, 2018, 6 pages (with English Translation). cited by applicant
Office Action in Israeli Patent Application No. 261066, dated Jul. 30, 2020, 6 pages (with English Translation). cited by applicant
Office Action in Israeli Patent Application No. 261066, dated May 5, 2019, 6 pages (with English Translation). cited by applicant
Office Action in Japanese Patent Application No. 2016-516354, dated Dec. 11, 2018, 6 pages (with English Translation). cited by applicant
Office Action in Japanese Patent Application No. 2018-505972, dated Sep. 23, 2020, 10 pages (with English Translation). cited by applicant
Office Action in Japanese Patent Application No. 2018-505994, dated Aug. 3, 2020, 8 pages (with English Translation). cited by applicant
Office Action in Japanese Patent Application No. 2018-505994, dated Oct. 5, 2020, 6 pages (with English Translation). cited by applicant
Office Action in Korean Patent Application No. 10-2016-7029770, dated Feb. 26, 2021, 7 pages (with English Translation). cited by applicant
Office Action in Korean Patent Application No. 10-2018-7024470, dated Dec. 21, 2020, 5 pages (with English Translation). cited by applicant
Office Action in Mexican Patent Application No. MX/a/2016/013667, dated Nov. 5, 2019, 8 pages (with English Translation). cited by applicant
Office Action in Mexican Patent Application No. MX/a/2018/010283, dated May 24, 2022, 8 pages (with English Translation). cited by applicant
Office Action in Pakistani Patent Application No. 234/2015, dated Jan. 18, 2021, 2 pages. cited by applicant
Office Action in Pakistani Patent Application No. 234/2015, dated Oct. 4, 2018, 2 pages. cited by applicant
Office Action in Russian Patent Application No. 2016146121, dated Nov. 28, 2018, 12 pages (with English Translation). cited by applicant
Office Action in Russian Patent Application No. 2018130530, dated Aug. 13, 2020, 16 pages (with

English Translation). cited by applicant
Office Action in Russian Patent Application No. 2018130530, dated Dec. 16, 2020, 6 pages (with English Translation). cited by applicant
Office Action in Russian Patent Application No. 2019119586, dated Jan. 25, 2022, 9 pages (with English Translation). cited by applicant
Office Action in Taiwanese Patent Application No. 104113328, dated Jan. 9, 2019, 7 pages (with English Translation). cited by applicant
Office Action in U.S. Appl. No. 15/305,049, dated Jan. 12, 2018, 8 pages. cited by applicant
Office Action in U.S. Appl. No. 15/305,049, dated Jul. 5, 2017, 12 pages. cited by applicant
Office Action in U.S. Appl. No. 15/305,049, dated Mar. 16, 2021, 5 pages. cited by applicant
Office Action in U.S. Appl. No. 15/305,049, dated Sep. 4, 2018, 13 pages. cited by applicant
Office Action in U.S. Appl. No. 16/078,557, dated May 12, 2021, 10 pages. cited by applicant
Office Action in U.S. Appl. No. 16/078,557, dated Nov. 17, 2020, 37 pages. cited by applicant
Office Action issued in Israeli Patent Application No. 248377, dated Jan. 15, 2018, 5 pages (with English translation). cited by applicant
Office Action issued in Pakistan Patent Application No. 234/2015, dated Oct. 6, 2017, 2 pages (English translation). cited by applicant
Official Receipt Payment of Request for Examination in Australian Patent Application No. 2015254307, dated Mar. 5, 2019, 1 page. cited by applicant
Official Receipt Payment of Request for Examination in Brazilian Patent Application No. BR112016025051-6, dated Mar. 7, 2018, 4 pages (with English Translation). cited by applicant
Ota et al., "Changes in Blood Concentration of Human Hepatocyte Growth Factor (hHGF) and Apolipoprotein A-IV After Transcatheter Arterial Embolization (TAE) in Hepatocyte Cancer Patients," The Japanese Journal of Clinical and Experimental Medicine, (1994), 71(8):245-247 (with English Translation). cited by applicant
Parr et al., "Expression of hepatocyte growth factor/scatter factor, its activator, inhibitors and the c-Met receptor in human cancer cells," International Journal of Oncology, Oct. 200, 19:857-863. cited by applicant
Preliminary Office Action with Technical Report in Brazilian Patent Application No. BR112016025051-6, dated Jun. 16, 2020, 8 pages (with English Translation). cited by applicant
Rafferty et al., "International Standards for hepatocyte growth factor/scatter factor: initial assessment of candidate materials and their evaluation by multicentre collaborative study", Journal of Immunological Methods, vol. 258, p. 1-11, 2001. cited by applicant
Request for Continued Examination filed in U.S. Appl. No. 15/305,049, dated Apr. 6, 2018, 15 pages. cited by applicant
Request for Continued Examination filed in U.S. Appl. No. 15/305,049, dated Mar. 25, 2019, 11 pages. cited by applicant
Request for Continued Examination filed in U.S. Appl. No. 15/305,049, filed Aug. 13, 2020, 3 pages. cited by applicant
Request for Continued Examination filed in U.S. Appl. No. 15/305,049, filed Aug. 25, 2021, 5 pages. cited by applicant
Request for Continued Examination filed in U.S. Appl. No. 15/305,049, dated Apr. 3, 2020, 9 pages. cited by applicant
Request for Continued Examination filed in U.S. Appl. No. 15/305,049, dated Feb. 19, 2020, 8 pages. cited by applicant
Request for Continued Examination filed in U.S. Appl. No. 15/305,049, dated Jan. 16, 2020, 8 pages. cited by applicant
Request for Continued Examination filed in U.S. Appl. No. 15/305,049, dated Jan. 7, 2021, 5 pages. cited by applicant
Request for Continued Examination filed in U.S. Appl. No. 15/305,049, dated May 20, 2021, 5

pages. cited by applicant
Request for Examination in Canadian Patent Application No. 2947396, dated Feb. 6, 2020, 1 page.
cited by applicant
Request for Examination in Chinese Patent Application No. 201580021294.9, filed on Oct. 26, 2016, 2 pages (with English Translation). cited by applicant
Request for Examination in Japanese Patent Application No. 2016-516354, filed on Feb. 29, 2018, 2 pages (with English Translation). cited by applicant
Request for Examination in Korean Patent Application No. 10-2016-7029770, filed on Nov. 18, 2019, 2 pages (with English Translation). cited by applicant
Request for Examination in Russian Patent Application No. 2016146121, dated Apr. 13, 2018, 2 pages (with English Translation). cited by applicant
Request for Examination in Russian Patent Application No. 2019119586, dated Jul. 29, 2021, 2 pages (with English Translation). cited by applicant
Request for Examination in Taiwanese Patent Application No. 104113328. dated Mar. 8, 2018, 6 pages (with English Translation). cited by applicant
Request for Examination with the Voluntary Amendment in Singaporean Patent Application No. 10201809228R, filed on Apr. 2, 2020, 10 pages. cited by applicant
Request for Examination, Form 18, in Indian Patent Application No. 201647036821, dated Feb. 23, 2018, 1 page. cited by applicant
Response and Amended Claims filed in European Patent Application No. 17766767.2, dated Nov. 19, 2019, 5 pages. cited by applicant
Response and Amendment filed in Australian Patent Application No. 2015254307, dated Oct. 10, 2019. 10 pages. cited by applicant
Response and Amendment filed in European Patent Application No. 17766718.5, dated Nov. 22, 2019, 9 pages. cited by applicant
Response and Amendment filed in European Patent Application No. 17766767.2, dated Jul. 19, 2021, 19 pages. cited by applicant
Response and Amendment filed in Israeli Patent Application No. 261066, dated Aug. 21, 2019, 5 pages (with English Translation). cited by applicant
Response and Amendment filed in Israeli Patent Application No. 261066, dated Aug. 27, 2020, 6 pages. cited by applicant
Response and Amendment filed in Korean Patent Application No. 10-2016-7029770, dated Apr. 22, 2021, 17 pages (with English Translation). cited by applicant
Response and Amendment filed in Russian Patent Application No. 2016146121, dated Apr. 17, 2019, 8 pages (with English Translation). cited by applicant
Response and Amendment for Pakistani Patent Application No. 234-2015, filed on Nov. 27, 2018, 4 pages. cited by applicant
Response and Claim Amendment filed in Chinese Patent Application No. 201780013057.7, dated Oct. 26, 2021, 10 pages (English Translation only). cited by applicant
Response and Claim Amendment filed in Russian Patent Application No. 2018130530, dated Feb. 8, 2021, 6 pages (with English Translation). cited by applicant
Response and Claim Amendment filed in Russian Patent Application No. 2018130530, dated Nov. 12, 2020, 10 pages (with English Translation). cited by applicant
Response file on Jul. 4, 2018, for the European Patent Application No. 15786509.8, 12 pages. cited by applicant
Response filed in Australian Patent Application No. 2015254307, dated Oct. 14, 2019, 4 pages. cited by applicant
Response filed in Australian Patent Application No. 2017232582, dated Jun. 20, 2022, 17 pages. cited by applicant
Response filed in Canadian Patent Application No. 2,947,396, dated Apr. 8, 2021, 8 pages. cited by

applicant

Response filed in Canadian Patent Application No. 3014567, dated Jun. 2, 2023, 8 pages. cited by applicant

Response filed in Chinese Patent Application No. 201580021294.9, dated Aug. 7, 2019, 16 pages (with English Translation). cited by applicant

Response filed in European Patent Application No. 17766767.2, dated Aug. 5, 2020, 7 pages. cited by applicant

Response filed in Indian Patent Application No. 201647036821, dated Apr. 14, 2020, 10 pages. cited by applicant

Response filed in Indian Patent Application No. 201847031049, dated Feb. 15, 2021, 8 pages. cited by applicant

Response filed in Korean Patent Application No. 10-2018-7024470, dated Feb. 9, 2021, 19 pages (with English Translation). cited by applicant

Response filed in Mexican Patent Application No. MX/a/2016/013667, dated Jan. 8, 2020, 10 pages (with English Translation). cited by applicant

Response filed in Mexican Patent Application No. MX/a/2018/010283, dated Jul. 1, 2022, 17 pages (with English Translation). cited by applicant

Response filed in Russian Patent Application No. 2019119586, dated Apr. 29, 2022, 9 pages (with English Translation). cited by applicant

Response filed in Taiwanese Patent Application No. 104113328, dated Mar. 25, 2019, 13 pages (with English Translation). cited by applicant

Response filed in U.S. Appl. No. 15/305,049, dated Apr. 9, 2021, 5 pages. cited by applicant

Response filed in U.S. Appl. No. 15/305,049, dated Dec. 16, 2019, 4 pages. cited by applicant

Response filed in U.S. Appl. No. 15/305,049, dated Nov. 1, 2018, 8 pages. cited by applicant

Response filed in U.S. Appl. No. 15/305,049, dated Oct. 26, 2017, 12 pages. cited by applicant

Response filed in U.S. Appl. No. 16/078,557, dated Feb. 17, 2021, 9 pages. cited by applicant

Response filed on May 11, 2018, for the Israeli Patent Application No. 248377, 2 pages (with English Translation). cited by applicant

Response to Office Action filed in Pakistani Patent Application No. 234/2015, dated Jan. 11, 2018, 7 pages. cited by applicant

Response to Office Action in Israeli Patent Application No. 248377, dated Feb. 26, 2019, 6 pages (with English Translation). cited by applicant

Response to Restriction Requirement filed in U.S. Appl. No. 16/078,557, filed Sep. 28, 2020, 3 pages. cited by applicant

Response to the Preliminary Office Action in Brazilian Patent Application No. BR112016025051-6, dated Sep. 8, 2020, to the Preliminary Office Action dated Jun. 16, 2020, 24 pages (with English Translation). cited by applicant

Restriction Requirement in U.S. Appl. No. 16/078,557, dated Aug. 26, 2020, 8 pages. cited by applicant

Search Report in Russian Patent Application No. 2016146121, dated Nov. 26, 2018, 6 pages (with English Translation). cited by applicant

Search Report in Russian Patent Application No. 2019119586, dated Jan. 24, 2022, 4 pages (with English Translation). cited by applicant

Selvarasu et al., "Combined In Silico Modeling and Metabolomics Analysis to Characterize Fed-Batch CHO Cell Culture," *Biotechnology and Bioengineering*, Jun. 2012, 109(6):1415-1429. cited by applicant

Shimomura et al., "A novel protease obtained from FBS-containing culture supernatant, that processes single chain form hepatocyte growth factor to two chain form in serum-free culture," *Cytotechnology*, 1992, 8(3):219-229. cited by applicant

Shimomura et al., *Journal of Biological Chemistry*, vol. 268, No. 30, Issue of Oct. 25, pp. 22927-

22932, 1993. cited by applicant
Sino Biological [online], "Human HGF/Hepatocyte Growth Factor Protein," Jun. 2012, [retrieved on Jun. 22, 2017], Retrieved from: URL<<http://www.sinobiological.com/HGF-Protein-g-5402.html>>, 3 pages. cited by applicant
Sino Biological [online], "Mouse HGF/Hepatocyte Growth Factor Protein," Jun. 2012, [retrieved on Jun. 22, 2017], Retrieved from: URL<<http://www.sinobiological.com/HGF-Hepatocyte-Growth-Factor-g-10551.html>>, 3 pages. cited by applicant
Stan et al., "Apo A-IV: an update on regulation and physiologic functions," *Biochimica et Biophysica Acta*, (2003), 1631(2):177-187. cited by applicant
Supplemental Response and Amendment filed in Israeli Patent Application No. 261066, dated Sep. 3, 2019, 5 pages (with English Translation). cited by applicant
Supplementary European Search Report issued in European Application No. 15786509.8 dated Jan. 3, 2018, 6 pages. cited by applicant
Suzuki et al., "Skeletal Muscle Injury Induces Hepatocyte Growth Factor Expression in Spleen," *Biochemical and Biophysical Research Communications*, 2002, 292:709-714. cited by applicant
Suzuki, Y. "Production Technology and Quality Problems of Freeze-Dried Parenteral Formulations", *Pharm. Tech. Japan*, vol. 8, No. 1, p. 75-87, 1992 (with English Translation). cited by applicant
Tahara et al., "Hepatocyte growth factor leads to recovery from alcohol-induced fatty liver in rats," *The Journal of Clinical Investigation*, (1999), 103(3):313-320. cited by applicant
Technical Report in Brazilian Patent Application No. 112016025051-6, issued on Mar. 5, 2020, 2 pages (with English Translation). cited by applicant
Telephonic Notice Response filed in Chinese Patent Application No. 201580021294.9, dated Aug. 26, 2019, 12 pages (with English Translation). cited by applicant
The Japanese Pharmacopoeia Sixteenth Edition, p. 113-116, 973-974 (Mar. 24, 2011) with English translation. cited by applicant
Voluntary Amendment filed in Taiwanese Patent Application No. 108125333, dated Jan. 15, 2020, 14 pages (with English Translation). cited by applicant
Written Argument and Amendment Response in Japanese Patent Application No. 2018-505972, dated Oct. 26, 2020, 9 pages (with English Translation). cited by applicant
Written Argument and Amendment Response in Japanese Patent Application No. 2018-505994, dated Aug. 25, 2020, 11 pages (with English Translation). cited by applicant
Written Argument and Amendment Response in Japanese Patent Application No. 2018-505994, dated Oct. 26, 2020, 6 pages (with English Translation). cited by applicant
Written Opinion in International Application No. PCT/JP2015/062523, dated Jul. 28, 2015, 4 pages (English translation). cited by applicant
Xu et al., "Transcriptional regulation of apolipoprotein A-IV by the transcription factor CREBH," *Journal of Lipid Research*, (2014), 55:850-859. cited by applicant
Xu et al., "Transforming growth factor-beta down-regulates apolipoprotein M in HepG2 cells," *Biochimica et Biophysica Acta*, (2004), 1683(1-3):33-37. cited by applicant
Office Action in Singaporean Patent Application No. 10202201622P, dated Apr. 9, 2025, 8 pages. cited by applicant
Response filed in Singaporean Patent Application No. 10202201622P, dated May 7, 2025, 5 pages. cited by applicant

Primary Examiner: Allen; Marianne P

Attorney, Agent or Firm: Fish & Richardson P.C.

Background/Summary

CROSS-REFERENCE TO RELATED APPLICATIONS (1) This application is a divisional of Ser. No. 17/737,343, filed on May 5, 2022, which is a continuation of U.S. application Ser. No. 16/078,568, filed on Aug. 21, 2018, now U.S. Pat. No. 11,548,926, which is the National Stage of International Application No. PCT/JP2017/010355, filed on Mar. 15, 2017 and claims the benefit of Japanese Application No. 2016-054128, filed on Mar. 17, 2016. The disclosures of the prior applications is incorporated herein by reference.

SEQUENCE LISTING

(1) This application contains a Sequence Listing that has been submitted electronically as an XML file named 38635-0011003_SL_ST26.xml. The XML file, created on Jan. 23, 2024, is 4,105 bytes in size. The material in the XML file is hereby incorporated by reference in its entirety.

TECHNICAL FIELD

(2) The present invention relates to a method for producing active hepatocyte growth factor activator (also referred to herein as “active HGFA”) and active hepatocyte growth factor (also referred to herein as “active HGF”) without using animal serum.

BACKGROUND ART

(3) HGF is a factor having hepatic parenchymal cell proliferation activity that is purified from the blood plasma of human fulminant hepatitis patients (Patent Literature 1 and Non-Patent Literature 1), and has been reported as having various pharmacological effects such as antitumoral effect, enhancement of cell-mediated immunity, wound therapeutic effect, and tissue regeneration promotional effect (Patent Literature 2).

(4) Until now, the gene encoding the aforementioned HGF has been cloned and produced by recombinant DNA technology (Patent Literatures 3-5). Moreover, it is known that HGF takes single-stranded and double-stranded forms which are composed of 2 types of subunits (a chain of approximately 60 kDa and β chain of approximately 30 kDa), where the single-stranded form does not have bioactivity and gains bioactivity in the double-stranded form. Further, it is known that in the production by recombinant DNA technology, HGF can be obtained as the active double-stranded form under culturing with animal serum, but under culturing without animal serum, the majority of the HGF produced is obtained as the inactive single-stranded form (e.g. Patent Literature 6). Since a protease contained in animal serum is involved in the conversion from the single-stranded inactive hepatocyte growth factor form (also referred to herein as “pro-HGF”) into the double-stranded active HGF form, it is thought necessary to use animal serum in order to efficiently obtain active HGF.

(5) On the other hand, in recent years, the mainstream in the production of biological material by recombinant DNA technology is culturing without animal serum in order to avoid the risk of virus contamination etc. Accordingly, in order to manufacture active HGF with a medium without animal serum, it is necessary to convert the single-stranded pro-HGF form into active HGF by some means. HGFA that can convert pro-HGF into active HGF (Patent Literature 7), or serine protease such as urokinase plasminogen activator (Non-Patent Literature 2) are known as such means. However, there are problems that these enzymes that can convert pro-HGF into active HGF are serum-derived, and when they are required to produce by integration of the gene into microorganisms or animal cells for production, they are produced as the precursor forms in a serum-free culture and therefore difficult to use as they are.

CITATION LIST

Patent Literatures

(6) [Patent Literature 1] Japanese Published Unexamined Patent Application Publication No. S63-22526 [Patent Literature 2] Japanese Patent No. 2747979 [Patent Literature 3] Japanese Patent No.

2577091 [Patent Literature 4] Japanese Patent No. 2859577 [Patent Literature 5] Japanese Patent No. 3072628 [Patent Literature 6] Japanese Patent No. 3213985 [Patent Literature 7] Japanese Published Unexamined Patent Application Publication No. H5-103670

Non-Patent Literatures

(7) [Non-Patent Literature 1] J. Clin. Invest., 81, 414(1988) [Non-Patent Literature 2] JGH 26(2011) Suppl. 1; 188-202, p. 192

SUMMARY OF THE INVENTION

Problems to be Solved by the Invention

(8) The object of the present invention is to provide a method for producing active HGFA and active HGF without using animal serum.

(9) The another object of the present invention is to provide active HGFA, active HGF, and preparations thereof produced by the method of the present invention.

Means for Solving the Problems

(10) As a result of extensive investigation by the present inventors to solve the above problems, it was found that by culturing mammalian cells expressing inactive hepatocyte growth factor activator (pro-HGFA) in a medium without serum to obtain the culture supernatant thereof, and subjecting the aforementioned culture supernatant to a particular treatment, pro-HGFA contained in the aforementioned culture supernatant can be converted into active HGFA. Accordingly, since pro-HGF produced under culturing without animal serum can be converted into active HGF by active HGFA similarly produced under culturing without animal serum, active HGF that does not contain animal serum-derived component or a preparation comprising the same can be produced.

(11) Accordingly, the present invention encompasses the following aspects: [1] A method for producing active hepatocyte growth factor activator (HGFA), characterized in that it comprises: Step 1: a step of obtaining a culture supernatant comprising pro-HGFA by culturing mammalian cells expressing inactive hepatocyte growth factor activator (pro-HGFA) in a medium without serum, and Step 2: a step of adjusting the culture supernatant comprising pro-HGFA obtained in the above step to weakly acidic to convert pro-HGFA into active HGFA. [2] The production method according to [1], characterized in that said step further comprises adding sulfated polysaccharides to said culture supernatant. [3] The production method according to [1] or [2], characterized in that said step of adjusting the culture supernatant to weakly acidic is a step of adjusting pH to 4.0-6.0. [4] The production method according to any of [1] to [3], characterized in that said step of adjusting the culture supernatant to weakly acidic is performed at a temperature of 15-40° C. [5] The production method according to any of [1] to [4], characterized in that said culture supernatant is obtained after a decline in the survival rate of mammalian cells in culture. [6] The production method according to any of [1] to [5], characterized in that said mammalian cell is a Chinese hamster ovary (CHO) cell. [7] The production method according to any of [1] to [6], characterized in that said pro-HGFA has the amino acid sequence shown in SEQ ID NO. 2. [8] The production method according to any of [1] to [7], characterized in that said culture supernatant is said culture supernatant per se, a dilution of said culture supernatant, a concentrate of said culture supernatant, or a partially purified product of said culture supernatant. [9] Active HGFA characterized in that it is obtained by the production method according to any of [1] to [8]. [10] A method for production active hepatocyte growth factor (HGF), characterized in that it comprises a step of allowing active HGFA to act on a culture supernatant comprising inactive hepatocyte growth factor (pro-HGF) to convert said pro-HGF into active HGF, wherein said culture supernatant comprising pro-HGF is a culture supernatant obtained by culturing cells expressing pro-HGF in a medium without serum, and said active HGFA is produced by the method according to any of [1] to [8]. [11] The production method according to [10], characterized in that said medium for culturing cells expressing pro-HGF is a medium without any animal-derived components. [12] The production method according to [10] or [11], characterized in that said pro-HGF has the amino acid sequence shown in SEQ ID NO. 1. [13] Active HGF characterized in that it is obtained by the production

method according to any of [10] to [12].

(12) Those skilled in the art shall recognize that an invention of any combination of one or more characteristics of the present invention described above is also encompassed by the scope of the present invention.

Effects of the Invention

(13) According to the present invention, a method for producing active HGFA and active HGF without using animal serum is provided.

(14) In the method for producing the active HGF of the present invention, since there is no need to use any animal serum in the production process thereof, a composition comprising the active HGF obtained by the aforementioned production method does not comprise animal serum-derived component and can be extremely safely applied to human.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) FIG. 1 shows that an HGFA culture supernatant prepared by activation of a pro-HGFA culture supernatant activates pro-HGF in a culture supernatant derived from CHO cells comprising pro-HGF.

(2) FIG. 2 shows the verification result employing design of experiments (DoE) regarding conditions under which the pro-HGFA culture supernatant is activated.

(3) FIG. 3 shows SDS-PAGE after chromatographic purification that employs a multimodal anion exchanger Capto Adhere as the chromatography support and 20 mM Tris-hydrochloride buffer (pH 8.0) comprising 0.25 M arginine and 0.7 M arginine as the eluent.

(4) FIG. 4 shows SDS-PAGE after chromatographic purification that employs a multimodal anion exchanger Capto Adhere as the chromatography support and 20 mM Tris-hydrochloride buffer (pH 8.0) comprising 1 M arginine as the eluent.

(5) FIG. 5 shows non-reductive and reductive SDS-PAGE results of the purified product at each stage of purification where purification similar to Example 5 was performed with a culture supernatant comprising pro-HGF that is not activated by a HGFA culture supernatant.

(6) FIG. 6 shows the result of measuring cell proliferation activity in the presence of TGF β for purified HGF obtained in Example 5.

DESCRIPTION OF EMBODIMENTS

(7) Reference herein to “active hepatocyte growth factor (active HGF),” unless otherwise explicitly shown, is construed as referring to the double-stranded activated HGF form, and is used in discrimination with inactive hepatocyte growth factor (pro-HGF) which is the single-stranded inactive form thereof.

(8) In the present invention, HGF may comprise HGF derived from humans, mice, rats, rabbits, or other animals. In the present invention, HGF is preferably HGF derived from humans.

(9) In the present invention, human HGF (hHGF) includes a polypeptide having the amino acid sequence shown in SEQ ID NO. 1 or a variant thereof. A variant of the polypeptide having the amino acid sequence shown in SEQ ID NO. 1 includes a polypeptide having an amino acid sequence having addition, deletion, or substitution of one or multiple amino acids to the amino acid sequence shown in SEQ ID NO. 1, as well as having HGF activity similar to or more than the polypeptide having the amino acid sequence shown in SEQ ID NO. 1 or which may be activated to have the activity. “Multiple” as used herein is 2-150, more preferably 2-80, more preferably 2-70, more preferably 2-60, more preferably 2-50, more preferably 2-40, more preferably 2-30, more preferably 2-20, more preferably 2-10, or more preferably 2-5.

(10) A variant of the polypeptide having the amino acid sequence shown in SEQ ID NO. 1 also includes a polypeptide having an amino acid sequence showing at least 80%, more preferably at

least 85%, and more preferably at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence shown in SEQ ID NO. 1, as well as having HGF activity similar to or more than the polypeptide having the amino acid sequence shown in SEQ ID NO. 1 or which may be activated to have the activity.

(11) A variant of the polypeptide having the amino acid sequence shown in SEQ ID NO. 1 also includes a polypeptide having the amino acid sequence encoded by a polynucleotide that hybridizes under stringent condition to a polynucleotide encoding the amino acid sequence shown in SEQ ID NO. 1, as well as having HGF activity similar to or more than the polypeptide having the amino acid sequence shown in SEQ ID NO. 1 or which may be activated to have the activity.

(12) In the present invention, a “stringent condition” can include those where in the post hybridization washing, hybridization is achieved with washing at for example a condition of “2×SSC, 0.1% SDS, 50° C.,” a condition of “2×SSC, 0.1% SDS, 42° C.,” or a condition of “1×SSC, 0.1% SDS, 37° C.,” and a more stringent condition can include those where hybridization is achieved with washing at for example conditions of “2×SSC, 0.1% SDS, 65° C.,” “0.5×SSC, 0.1% SDS, 42° C.,” “0.2×SSC, 0.1% SDS, 65° C.,” or “0.1×SSC, 0.1% SDS, 65° C.” (1×SSC is 150 mM sodium chloride, 15 mM sodium citrate, pH 7.0). More particularly, as a method that employs Rapid-hyb buffer (Amersham Life Science), it is conceivable to perform prehybridization at 68° C. for 30 minutes or more, after which a probe is added and retained at 68° C. for 1 hour or more to allow formation of hybrids, and then to perform three washes in 2×SSC and 0.1% SDS at room temperature for 20 minutes, three washes in 1×SSC and 0.1% SDS at 37° C. for 20 minutes, and finally two washes in 1×SSC and 0.1% SDS at 50° C. for 20 minutes. More preferably, using a solution, for example, comprising 5×SSC, 7% (W/V) SDS, 100 µg/mL denatured salmon sperm DNA, and 5×Denhardt's solution (1×Denhardt's solution comprises 0.2% polyvinylpyrrolidone, 0.2% bovine serum albumin, and 0.2% Ficoll) as prehybridization and hybridization solutions, prehybridization is performed at 65° C. for 30 minutes to 1 hour and hybridization is performed at the same temperature overnight (6-8 hours). In addition, it is also possible to perform for example prehybridization in Expresshyb Hybridization Solution (CLONTECH) at 55° C. for 30 minutes or more, add a labeled probe and incubate at 37-55° C. for 1 hour or more, and three washes in 2×SSC and 0.1% SDS at room temperature for 20 minutes and then one washing in 1×SSC and 0.1% SDS at 37° C. for 20 minutes. Here, a more stringent condition can be achieved for example by raising the temperature for prehybridization, hybridization, or second washing. For example, the temperature for prehybridization and hybridization can be 60° C., or 65° C. or 68° C. for a further stringent condition. Those skilled in the art will be able to set conditions for obtaining isoforms, allelic variants, and corresponding genes derived from other organism species for the gene of the present invention by factoring in various conditions such as other probe concentration, probe length, and reaction time in addition to conditions such as salt concentration of such a buffer and temperature. For a detailed protocol of the hybridization method, reference can be made to “Molecular Cloning, A Laboratory Manual 2nd ed.” (Cold Spring Harbor Press (1989); in particular Section 9.47-9.58), “Current Protocols in Molecular Biology” (John Wiley & Sons (1987-1997); in particular Section 6.3-6.4), “DNA Cloning 1: Core Techniques, A Practical Approach 2nd ed.” (Oxford University (1995); in particular Section 2.10 for conditions), and the like.

(13) Reference herein to “active hepatocyte growth factor activator (active HGFA),” unless otherwise explicitly shown, is construed as referring to activated HGFA, and is used in discrimination with inactive hepatocyte growth factor activator (pro-HGFA) which is the inactive form thereof.

(14) In the present invention, HGFA may include HGFA derived from human, mouse, rat, rabbit, or other animals. In the present invention, HGFA is preferably HGFA derived from humans.

(15) In the present invention, human HGFA includes a polypeptide having an amino acid sequence shown in SEQ ID NO. 2 or a variant thereof. The variant of the polypeptide having the amino acid

sequence shown in SEQ ID NO. 2 includes a polypeptide having an amino acid sequence having addition, deletion, or substitution of one or multiple amino acids to the amino acid sequence shown in SEQ ID NO. 2, as well as having HGF activity similar to or more than the polypeptide having the amino acid sequence shown in SEQ ID NO. 2 or which may be activated to have the activity. "Multiple" as used herein is 2-150, more preferably 2-80, more preferably 2-70, more preferably 2-60, more preferably 2-50, more preferably 2-40, more preferably 2-30, more preferably 2-20, more preferably 2-10, or more preferably 2-5.

(16) The variant of the polypeptide having the amino acid sequence shown in SEQ ID NO. 2 also includes a polypeptide having an amino acid sequence showing at least 80%, more preferably at least 85%, and more preferably at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence shown in SEQ ID NO. 2, as well as having HGFA activity similar to or more than the polypeptide having the amino acid sequence shown in SEQ ID NO. 2 or which may be activated to have the activity.

(17) The variant of the polypeptide having the amino acid sequence shown in SEQ ID NO. 2 also includes a polypeptide having the amino acid sequence encoded by a polynucleotide that hybridizes under stringent condition to a polynucleotide encoding the amino acid sequence shown in SEQ ID NO. 2, as well as having HGF activity similar to or more than the polypeptide having the amino acid sequence shown in SEQ ID NO. 2 or which may be activated to have the activity.

(18) The present invention is described in detail below.

(19) In one aspect, the present invention relates to a method for producing active HGFA without using animal serum. Specifically, the method for producing the active HGFA of the present invention is a method for producing active HGFA by subjecting a culture supernatant comprising pro-HGFA recombinantly expressed in mammalian cells to a given treatment to thereby allow conversion into active HGFA. Since animal serum is not used in the conversion into active HGFA, according to the present method, the pro-HGFA obtained or a composition comprising the same has significantly lower possibility of inviting the risk of being contaminated with infective materials such as virus derived from cells of other animal species or other individuals, and can be employed for various purposes as a highly safe biological material.

(20) Specifically, in one embodiment, the method for producing the active HGFA of the present invention is characterized in that it comprises the following steps:

Step 1

(21) a step of obtaining a culture supernatant comprising pro-HGFA by culturing mammalian cells expressing pro-HGFA in a medium without serum, and

Step 2

(22) a step of adjusting the culture supernatant comprising pro-HGFA obtained in the above step to weakly acidic to convert pro-HGFA into active HGFA.

(23) In another embodiment, the HGFA production method of the present invention is characterized in that it comprises a step of adjusting the culture supernatant comprising pro-HGFA to weakly acidic to convert pro-HGFA into active HGFA, wherein said culture supernatant is a culture supernatant obtained by culturing mammalian cells expressing pro-HGFA in a medium without serum.

(24) Weak acidification of the culture supernatant is a treatment for converting pro-HGFA into active HGFA. Since conversion from pro-HGFA into active HGFA occurs by weak acidification alone without externally adding enzymes etc. to the culture supernatant, mammalian cell-derived components are thought to be involved in the conversion from pro-HGFA into active HGFA, and weak acidification is a means for activating said mammalian cell-derived components. Weak acidification may be performed by means well-known to those skilled in the art, such as adding for example an acidic solution (inorganic acids such as hydrochloric acid, sulfuric acid, and phosphoric acid, or organic acids such as acetic acid, succinic acid, and citric acid) at an appropriate concentration. In one embodiment of the present invention, "weakly acidic" is a range of pH 4.0-

6.0, preferably 5.0-6.0, and more preferably 5.3-5.6, for example pH 5.5.

(25) In the present invention, a “culture supernatant comprising pro-HGFA” (also referred to herein as a “pro-HGFA culture supernatant”) is a fraction comprising pro-HGFA that is obtained by cell culturing mammalian cells expressing pro-HGFA, which can be obtained from a cell culture of said mammalian cells by those skilled in the art according to conventional means. For example, the pro-HGFA culture supernatant may be a fraction where residues are removed from a cell culture of said mammalian cells by a means such as centrifugation.

(26) In the present invention, the culture supernatant may be any fraction prepared by applying any treatment to the culture supernatant to an extent that the biological activity of pro-HGFA is not lost. Accordingly, in the present invention, the culture supernatant includes, but is not limited to, the culture supernatant per se, and a dilution, a concentrate or a partially purified product of the culture supernatant.

(27) In a preferred embodiment of the present invention, the “step of converting pro-HGFA into active HGFA” further comprises adding sulfated polysaccharides to said culture supernatant. By adding sulfated polysaccharides, the conversion from pro-HGFA into active HGFA can be performed more efficiently. The timing for adding sulfated polysaccharides may be at any time point of before weak acidification of said culture supernatant, simultaneously with weak acidification, or after weak acidification. Moreover, the amount of sulfated polysaccharides added may vary depending on e.g. the type of sulfated polysaccharides used, and may be added at an amount of 0.01-50 mg, more preferably 0.1-20 mg, for example 1 mg per 1 mL of said pro-HGFA culture supernatant.

(28) Sulfated polysaccharides that can be used for the method for producing the active HGFA of the present invention can include, but are not limited to, heparin, dextran sulfate, chondroitin sulfate, fucoidan, and salts thereof. In a preferred embodiment of the present invention, dextran sulfate is used.

(29) In a preferred embodiment of the present invention, the “step of converting pro-HGFA into active HGFA” is performed at a temperature of 15-40° C., preferably 20-37° C., for example 25° C. By employing said temperature range, the conversion of pro-HGFA into active HGFA can be made more efficient.

(30) In the method for producing the active HGFA of the present invention, the “step of converting pro-HGFA into active HGFA” is performed for a length of time sufficient to recognize the desired HGFA activity after weak acidification. Such a length of time may vary depending on pH, the presence or absence of sulfated polysaccharide used in combination, and temperature condition etc., and can be 1-15 hours, for example 6-8 hours after weak acidification.

(31) In one embodiment of the present invention, the pro-HGFA culture supernatant is a culture supernatant that is obtained after a decline in the survival rate of mammalian cells in culture. Along with the decline in the survival rate of the mammalian cells, the animal cell-derived components involved in the conversion from pro-HGFA into active HGFA are eluted out from dead cells, and can be sufficiently collected in the pro-HGFA culture supernatant. The “decline in the survival rate of mammalian cells in culture” herein refers to the decline in the survival rate of the mammalian cells after proliferation to maximum cell density. In the present invention, the survival rate of mammalian cells in the pro-HGFA culture supernatant is preferably 95% or less, more preferably 80% or less, for example 70%.

(32) Since an enzyme derived from host cell lysosome is thought to be involved in the activation from pro-HGFA to active HGFA, an enzyme derived from lysosome may be added to apply treatment.

(33) Mammalian cells that can be used in the method for producing the active HGFA of the present invention can include, but are not limited to, Chinese hamster ovary (CHO) cells, HeLa cells, HEK cells (including HEK 293 cells), COS cells, NS0 mouse myeloma cells, Sp2/0 mouse myeloma cells, and the like. In a preferred embodiment of the present invention, CHO cells are used as

mammalian cells expressing pro-HGFA.

(34) The present invention also relates to a composition comprising active HGFA or active HGFA produced by the method for producing the active HGFA of the present invention. Since the composition comprising active HGFA or active HGFA of the present invention can be produced without using animal serum from recombinantly expressed pro-HGFA without using animal serum, it can be used as a highly safe biological material e.g. for the method for producing the active HGF described below.

(35) In another aspect, the present invention relates to a method for producing active HGF. The method for producing the active HGF of the present invention comprises allowing active HGFA obtained by the method for producing the active HGFA of the present invention to act on a culture supernatant comprising pro-HGF recombinantly expressed in a medium similarly without serum to convert pro-HGF into active HGF. According to this method, since active HGF can be produced without employing animal serum in all of the steps including obtaining active HGFA employed for conversion into active HGF, the active HGF obtained or a composition comprising the same can be used as a highly safe pharmaceutical material that eliminates the risk of being contaminated with infective materials such as virus.

(36) Specifically, in one embodiment, the method for producing the active HGF of the present invention is characterized in that it comprises a step of allowing active HGFA to act on a culture supernatant comprising pro-HGF to convert said pro-HGF into active HGF, wherein said culture supernatant comprising pro-HGF is a culture supernatant obtained by culturing cells expressing pro-HGF in a medium without serum, and said active HGFA is produced by the above method for producing the active HGFA of the present invention.

(37) Moreover, in another embodiment, the method for producing the active HGF of the present invention is characterized in that it comprises the following steps:

Step A

(38) a step of adjusting the culture supernatant comprising pro-HGFA to weakly acidic to convert pro-HGFA into active HGFA, wherein said culture supernatant is a culture supernatant obtained by culturing mammalian cells expressing pro-HGFA in a medium without serum,

Step B

(39) a step of obtaining a culture supernatant comprising pro-HGF by culturing cells expressing pro-HGF in a medium without serum,

Step C

(40) a step of allowing the active HGFA obtained in said step A to act on the culture supernatant comprising pro-HGF obtained in said step B to convert said pro-HGF into active HGF.

(41) In the present invention, a “culture supernatant comprising pro-HGF” is a fraction comprising pro-HGF that is obtained by culturing cells expressing pro-HGF, and those skilled in the art can obtain the same from a culture of said cells according to conventional means. For example, a culture supernatant comprising pro-HGF may be a fraction where residues are removed from a culture of said cells by a means such as centrifugation.

(42) In the method for producing the active HGF of the present invention, a culture supernatant obtained by culturing mammalian cells expressing pro-HGFA in a medium without serum may be employed as it is, or a dilution, a concentrate, or a partially or completely purified product of the aforementioned culture supernatant may be employed as the active HGFA that is allowed to act on the “culture supernatant comprising pro-HGF.”

(43) In the present invention, a mammalian cell expressing pro-HGFA can be obtained by, but not limited to, creating a vector comprising a nucleic acid encoding pro-HGFA, and introducing this into a host cell mammalian cell to allow transformation. Similarly, a cell expressing pro-HGF can be obtained by creating a vector comprising a nucleic acid encoding pro-HGF, and introducing this into a host cell to allow transformation.

(44) A gene expression vector etc. can be used as the above-described vector. A “gene expression

vector” is a vector which has the function to express the base sequence that the nucleic acid of interest has, and may include a promoter sequence, an enhancer sequence, a repressor sequence, an insulator sequence, and the like for controlling the expression of said base sequence. These sequences are not particularly limited as long as they function in the host cell.

(45) The means to create the vector comprising the nucleic acid of interest is well-known to those skilled in the art, and those skilled in the art can suitably select an appropriate method. For example, such a means can include, but is not limited to, a ligase reaction that utilizes a restriction enzyme site and the like (Current Protocols in Molecular Biology, John Wiley & Sons (1987) Section 11.4-11.11; Molecular Cloning, A Laboratory Manual 2nd ed., Cold Spring Harbor Press (1989) Section 5.61-5.63).

(46) The cells expressing pro-HGF are not particularly limited as long as they can express pro-HGF, and include, for example, insect cells, eukaryotic cells, mammalian cells. Preferably, in terms of efficiently expressing a nucleic acid encoding pro-HGF derived from human, mammalian cells, e.g., CHO cells, HEK cells (including HEK 293 cells), HeLa cells, NS0 cells, or SP2/0 mouse myeloma cells are used. In a preferred embodiment of the invention, CHO cells are used as the mammalian cell expressing pro-HGF.

(47) The means for introducing the above vector into a host cell is well-known, and those skilled in the art can suitably select an appropriate method. Examples can include, but are not limited to, for introduction of a vector into a host cell, electroporation method (Chu et al. (1987) Nucleic Acids Res. 15: 1311-26), cationic liposome method, electrical pulse perforation method (Current Protocols in Molecular Biology, John Wiley & Sons (1987) Section 9.1-9.9), direct inject method using a capillary glass tube, microinjection method, lipofection (Derijard (1994) Cell 7: 1025-37; Lamb (1993) Nature Genetics 5: 22-30; Rabindran et al. (1993) Science 259: 230-4), lipofectamine method (Thermo Fisher Scientific), calcium phosphate method (Chen and Okayama (1987) Mol. Cell. Biol. 7: 2745-52), DEAE dextran method (Lopata et al. (1984) Nucleic Acids Res. 12: 5707-17; Sussman and Milman (1985) Mol. Cell. Biol. 4: 1642-3), FreeStyle MAX Reagent (Thermo Fisher Scientific), and the like.

(48) In regards to the serum-free medium used for culturing cells expressing pro-HGFA and cells expressing pro-HGF, those skilled in the art can suitably select an appropriate composition depending on the type of host cell etc. used. Moreover, other culture conditions can also be suitably selected by those skilled in the art, and for example, but not limited to, the culture temperature can be suitably selected from between 35.5-37.5° C., and the culture period can be selected from between 5-20 days. For pro-HGFA, the culture period may be set according to the target survival rate. The carbon dioxide concentration during culture can be 5% CO₂ in accordance to the general protocol.

(49) In one embodiment, the method for producing the active HGF of the present invention is characterized in that followed by said step, it further comprises a step of purifying active HGF. This step may include purification of pro-HGF that may remain in the preparation comprising active HGF.

(50) The purification method that may be used in the present invention is not particularly limited as long as it enables purification without losing the physiologic activity of the protein. In particular, it is preferred to use chromatographic purification employing a mixed mode support in the present invention.

(51) Mixed mode support is also referred to as mixture mode support, and is a chromatography support in which ligands of modes with two or more types of properties are bound into one support. In particular, in the present invention, for the purification of active HGF, active HGF can be efficiently purified by chromatographic purification employing a mixed mode support having characteristics of hydrophobicity and ion exchange support.

(52) Examples of a “mixed mode support having characteristics of hydrophobicity and ion exchange support” that may be used in the method of the present invention can include, but are not

limited to, Capto adhere, Capto MMC, HEA HyperCel, PPA HyperCel, MEP HyperCel, TOYOPEARL MX-Trp-650M, and the like.

(53) Chromatographic purification employing said mixed mode support can be performed by adsorbing active HGF in the column loading solution to said mixed mode support, and then washing with a buffer to remove impurities, followed by elution. The buffer for removing impurities can be set based on the pH, electric conductivity, buffer component, salt concentration, or additives that maintain the adsorption between the protein which is the target for purification and the support while reducing the affinity between impurities and the support.

(54) Examples of the column loading solution and buffer used include, but are not limited to, phosphate salts, citrate salts, acetate salts, succinate salts, maleate salts, borate salts, Tris (base), HEPES, MES, PIPES, MOPS, TES, or Tricine and the like.

(55) The column loading solution and buffer used can comprise amino acids. Examples of such amino acids can include, but are not limited to, glycine, alanine, arginine, serine, threonine, glutamic acid, aspartic acid, histidine, derivatives thereof, and the like.

(56) In the present invention, a column loading solution that has suitable pH and salt concentration for adsorbing active HGF onto said mixed mode support can be used. Such a pH range is pH 6.0-10.0, more preferably pH 7.0-9.0, for example pH 8.0. Moreover, such a salt concentration is 0.01-5 M, preferably 0.1-2 M, for example 1 M. The above salt concentration can be prepared by employing for example 0.001 M-4 M sodium chloride, potassium chloride, calcium chloride, sodium citrate, sodium sulfate, ammonium sulfate, or a combination thereof.

(57) In the present invention, elution of active HGF can be performed by employing a buffer that will reduce the affinity between said mixed mode support and active HGF. Such a buffer includes a buffer comprising at least 0.1 M arginine, more preferably at least 0.3 M arginine, further preferably at least 0.4 M arginine, for example 0.7 M arginine. Moreover, in combination with or instead of arginine, a buffer comprising magnesium ion (Mg.sup.2+) can also be employed. Alternatively, elution of active HGF may also be performed by a stepwise method that reduces pH stepwise to elute active HGF.

(58) In one embodiment of the present invention, said purification may further comprise, after purification by a mixture mode support comprising an ion exchange group and a hydrophobic interaction group, purification by single or multiple additional chromatographies. This will enable active HGF to be obtained at higher purity. Such a chromatographic purification includes, but is not limited to, for example chromatographic purification that employs a mixed mode support, an anion exchange support, a cation exchange support, a hydrophobic interaction support, a size exclusion support, a gel filtration support, a reverse phase support, a hydroxyapatite support, a fluoroapatite support, a sulfated cellulose support, or a sulfated agarose support and the like.

(59) Note that the terms used herein are to be employed to describe particular embodiments and do not intend to limit the invention.

(60) Moreover, the term “comprising” as used herein, unless the content clearly indicates to be understood otherwise, intends the presence of the described items (such as components, steps, elements, and numbers), and does not exclude the presence of other items (such as components, steps, elements, and numbers).

(61) Unless otherwise defined, all terms used herein (including technical and scientific terms) have the same meanings as those broadly recognized by those skilled in the art of the technology to which the present invention belongs. The terms used herein, unless explicitly defined otherwise, are to be construed as having meanings consistent with the meanings herein and in related technical fields, and shall not be construed as having idealized or excessively formal meanings.

(62) Terms such as first and second are sometimes employed to express various elements, and it should be recognized that these elements are not to be limited by these terms. These terms are employed solely for the purpose of discriminating one element from another, and it is for example possible to describe a first element as a second element, and similarly, to describe a second element

as a first element without departing from the scope of the present invention.

(63) The present invention will now be more specifically described by Examples. However, the present invention can be embodied by various embodiments, and shall not be construed as being limited to the Examples described herein.

EXAMPLES

(64) The present invention will be specifically described below by showing Examples, but the present invention is not to be limited by the Examples.

Example 1

(65) CHO cells that recombinantly express full length pro-HGFA were thawed in EX-CELL custom design medium (from SAFC) in a T75 flask (from Corning, 430421), expansion culture was performed in a 250 mL shaker flask (from Corning, 431144), and then cultured for 10 days in a 7 L culture tank (from ABLE/Biott, BCP-07) at 121 rpm set at 36.5° C. The survival rate of the cells at Day 10 of culturing was 47.1%. After completion of culture, cells were removed by centrifugation and microfiltered through a 0.2 m filter (from Sartorius, 5445307H7-00), and the pro-HGFA supernatant collected was stored under refrigeration until use.

(66) 50 mL of pro-HGFA culture supernatant obtained similarly as above was placed in a 100 mL glass beaker, 5 mL, which is 1/10 volume of the supernatant, of 10 g/L aqueous solution of dextran sodium sulfate (Mw. 500,000) was added, and then pH was adjusted to 5.3 with 2 M hydrochloric acid. After the pH adjustment, it was subjected to filtration with a 0.2 m filter, and then placed in a 250 mL shaker flask. Five percent carbon dioxide was blown in for 60 seconds, and then reaction was performed at room temperature with stirring speed set at 80 rpm for 6 hours. The activation reaction was progressed at around pH 5.5. Sampling was performed after 6 hours of reaction, and HGFA activity was measured with synthetic peptide as the substrate. The synthetic substrate H-D-Val-Leu-Arg-pNA.2AcOH (from Bachem, L-1885) was dissolved in 50 mM Tris-HCl—0.15 M sodium chloride—10 mM calcium chloride buffer (pH 7.5) comprising 0.25% BSA, and adjusted to 2 mM. This was applied at 100 µL/well in the necessary number of wells in a 96-well plate, and 10 µL each of the HGFA culture supernatant which had been subjected to activation treatment, positive control, and untreated pro-HGFA culture supernatant were added. As the positive control, HGFA culture supernatant which had been activated in advance and was confirmed to be capable of sufficiently activating pro-HGF was employed. The plate was shielded from light with an aluminum foil, and incubated at 37° C. for 1 hour. Absorbance was read with a plate reader from TECAN (405 nm), and HGFA activity value was calculated by subtracting an absorbance of untreated pro-HGFA culture supernatant from the original absorbance. As a result, it was confirmed that the activity value of the HGFA sample after activation showed 0.577, which is comparable to the activity value of the positive control. It is thought that pro-HGFA is activated by the action of an enzyme derived from the host CHO cell since any enzymes and the like were not externally added to this reaction solution. Moreover, when 1 M Tris was added to the solution after 7.6 hours of reaction to adjust pH to 7.0 and then the solution was stored under refrigeration for 2 days to examine the change in HGFA activity value, a large decline in the activity value was not seen with the activity value immediately after neutralization at 0.653, Day 1 of refrigeration at 0.667, and Day 2 of refrigeration at 0.679, showing stability for 2 days after activation (Table 1).

(67) TABLE-US-00001 TABLE 1 HGFA Activity Value After Activation Treatment HGFA Activity Value Measurement 1 Pro-HGFA 0.100 — culture supernatant 6 hours after 0.677 0.577 activation Positive-control 0.709 0.609 Measurement 2 Pro-HGFA 0.110 — culture supernatant 7.6 hours after 0.803 0.693 activation (before neutralization) 7.6 hours after 0.763 0.653 activation (after neutralization) Day 1 of 0.777 0.667 refrigerated storage after neutralization Day 2 of 0.789 0.679 refrigerated storage after neutralization Positive-control 0.714 0.604

(68) CHO cells that recombinantly express pro-HGF were thawed in EX-CELL custom design medium in a T75 flask, expansion culture was performed in a 250 mL shaker flask and a 7 L culture tank, and this was then cultured for 9 days in a 20 L culture tank at 144 rpm set at 36.5° C.

The survival rate at Day 9 of culturing was 90.6%. After filtration to remove cells, 19.14 kg of pro-HGF culture supernatant that had been microfiltered through a 0.2 μm filter (from Sartorius, 5445307H9-00) was charged into a 30 L culture tank. To this, 0.96 kg, which is 1/20 volume of the HGF supernatant, of the HGFA culture supernatant that had been activated and returned to pH 7.0 and stored under refrigeration for 2 days was added and reacted with stirring at 30 rpm at 25° C. Note that the activated HGFA culture supernatant charged was that which had an activity value comparable to the positive control in HGFA activity measurement. Sampling was performed after about 20 hours of reaction, and the activation state of pro-HGF was confirmed with SDS-PAGE employing 5-20% polyacrylamide gel (from DRC, NXV-271HP). A band of single strand was seen under a non-reductive condition, and under a reductive condition after activation the single strand substance had disappeared and separated into α and β chains, and thus sufficient activation of pro-HGF was confirmed (FIG. 1).

Example 2

(69) Using design of experiments (DoE), the validity of pro-HGFA activation parameters described in Example 1 which are pH (5.3-5.5) and reaction temperature (room temperature) was tested. Experiment conditions were set with central composite design using JMP software (from SAS Institute), and a solution for pro-HGFA activation treatment was prepared similarly to the method described in Example 1. Note that pH was adjusted to three conditions of pH 5.0, 5.5, and 6.0 with 2 M hydrochloric acid. 100 μL each were placed in 1.5 mL tubes and reacted by still standing at 20° C., 28.5° C. and 37° C. Sampling was performed after 3, 6, 9, and 15 hours of reaction, and HGFA activity measured with synthetic peptide as the substrate. HGFA activity value is obtained by subtracting the value (A405) of untreated pro-HGFA culture supernatant. A response surface plot was created by statistical analysis from the HGFA activity values obtained from a total of 27 conditions, and the range having an activity value of 0.4 or more was shown in white. From this result, it was found that the condition that gives the highest HGFA activity value is pH 5.4 and a reaction temperature of 26.1° C., and that HGFA activity value can be obtained in a wide range (FIG. 2).

Example 3

(70) 2 mL of multimodal anion exchanger Capto Adhere (from GE Healthcare, 28-4058-44) was equilibrated in advance with 20 mM Tris-hydrochloride buffer (pH 8.0) comprising 2 M sodium chloride. To 32 mL of culture supernatant comprising active HGF, sodium chloride was added to obtain 1 M. This culture supernatant was loaded onto the column at a flow rate of 2 mL/min and the flow-through solution was collected. After loading was complete, 20 mM Tris-hydrochloride buffer (pH 8.0) comprising 2 M sodium chloride was flowed at an amount corresponding to 3 times of the column volume to wash, and the eluate was collected. After washing was complete, 20 mM Tris-hydrochloride buffer (pH 8.0) comprising 0.25 M arginine was flowed at an amount corresponding to 3 times of the column volume to wash and the eluate was collected. Next, an operation to flow 20 mM Tris-hydrochloride buffer (pH 8.0) comprising 0.7 M arginine at an amount corresponding to 1 column volume to collect the eluate was repeated 5 times. Finally, 20 mM Tris-hydrochloride buffer (pH 8.0) comprising 1.0 M arginine was flowed at an amount corresponding to 3 times of the column volume to collect the eluate. FIG. 3 shows the result of performing SDS-PAGE under a non-reductive condition with the solutions collected in this process. The gel for SDS-PAGE employed was XV-PANTERA (NXV-271HP) from DRC, and the molecular weight marker employed was Precision Plus Protein All Blue Standards (161-0373) from BIORAD. The samples were subjected to SDS-PAGE analysis after performing 10 minutes of heat treatment in Laemmli's sample buffer at 60° C. Electrophoresis was performed under a constant voltage of 150 V, and the gel was stained when the electrophoresis was complete with PAGE Blue83 from COSMO BIO to confirm the separated proteins. When comparing the column loading solution and the flow-through solution, the HGF band of molecular weight of around 75,000 was decreased in the flow-through solution, showing that it was adsorbed onto the support. HGF was

not eluted by flowing through 20 mM Tris-hydrochloride buffer (pH 8.0) comprising 2 M sodium chloride. A component comprising much impurity was eluted in subsequent washing with 20 mM Tris-hydrochloride buffer (pH 8.0) comprising 0.25 M arginine. Active HGF was then eluted by flowing through 20 mM Tris-hydrochloride buffer (pH 8.0) comprising 0.7 M arginine.

Example 4

(71) 1 mL of multimodal anion exchanger Capto Adhere (from GE Healthcare, 28-4058-44) was equilibrated in advance with 20 mM Tris-hydrochloride buffer (pH 8.0) comprising 2 M sodium chloride. To 8 mL of culture supernatant comprising active HGF was added an equal amount of 20 mM Tris-hydrochloride buffer (pH 8.0) comprising 2 M sodium chloride to obtain 1 M. This culture supernatant was loaded onto the column and the flow-through solution was collected. After loading was complete, 20 mM Tris-hydrochloride buffer (pH 8.0) comprising 2 M sodium chloride was flowed at an amount corresponding to 3 times of the column volume to wash, and the eluate was collected. An amount corresponding to 5 times of the column volume of 20 mM Tris-hydrochloride buffer (pH 8.0) comprising 1 M arginine was flowed, and the eluate was collected. FIG. 4 shows the result of performing SDS-PAGE under a non-reductive condition with the solutions collected in this process. The gel for SDS-PAGE employed was XV-PANTERA (NXV-271HP) from DRC, and the molecular weight marker employed was Precision Plus Protein All Blue Standards (161-0373) from BIORAD. The samples were subjected to SDS-PAGE analysis after performing 10 minutes of heat treatment in Laemmli's sample buffer at 60° C. Electrophoresis was performed under a constant voltage of 150 V, and the gel was stained when the electrophoresis was complete with PAGE Blue83 from COSMO BIO to confirm the separated proteins. When comparing the column loading solution and the flow-through solution, HGF band was decreased in the flow-through solution, showing that it was adsorbed onto the support. HGF was not eluted by flowing through 20 mM Tris-hydrochloride buffer (pH 8.0) comprising 2 M sodium chloride. Active HGF was eluted with the subsequent elution with 20 mM Tris-hydrochloride buffer (pH 8.0) comprising 1 M arginine.

Example 5

(72) To the culture supernatant comprising active HGF obtained in the method of Example 1 was added an equal amount of 40 mM Tris-hydrochloride buffer (pH 8.0) comprising 2 M sodium chloride, and then the pH was adjusted to 8.0. The above solution was loaded onto a Capto adhere (GE Healthcare, 17-5444-05) column equilibrated with 20 mM Tris-hydrochloride buffer (pH 8.0) comprising 2 M sodium chloride, and after loading was complete, washing with the buffer employed for equilibration was performed. The column was washed with 20 mM Tris-hydrochloride buffer (pH 8.0) comprising 0.25 M arginine hydrochloric acid, after which it was eluted with 20 mM Tris-hydrochloride buffer (pH 8.0) comprising 0.7 M arginine hydrochloric acid, and the fraction comprising HGF was collected.

(73) The Capto adhere purification fraction was pooled, the solution diluted 7 times with 20 mM Tris-hydrochloride buffer (pH 7.5) comprising 0.012% polysorbate 80 was loaded onto a Capto Q (GE Healthcare, 17-5316-05) column equilibrated with 20 mM Tris-hydrochloride buffer (pH 7.5) comprising 0.012% polysorbate 80, and after loading was complete, washing with the buffer employed for equilibration was performed. The column flow-through solution and the wash solution were pooled as the Capto Q purification fraction.

(74) The Capto Q purification fraction was loaded onto a UNOsphere S (Bio-Rad 156-0117) column equilibrated with 20 mM phosphate buffer (pH 7.5), and after loading was complete, this was washed with the buffer employed for equilibration. After completion of washing with the same solution, this was washed with 20 mM phosphate buffer (pH 7.5) comprising 0.4 M sodium chloride, and then the adsorbed HGF was eluted with 20 mM phosphate buffer (pH 7.5) comprising 0.6 M sodium chloride as the UNOsphere S purification fraction.

(75) To the UNOsphere S purification fraction was added 20 mM phosphate buffer (pH 7.5) comprising 5 M sodium chloride to adjust the sodium chloride concentration of the solution to 3.3

M and the pH to 7.5. Phenyl Sepharose HP (GE Healthcare, 17-1082-04 column) was equilibrated with 20 mM phosphate buffer (pH 7.5) comprising 3.3 M sodium chloride, and then the above HGF solution was loaded. After loading was complete, the column was washed with the buffer employed for equilibration. The adsorbed HGF was eluted by a linear gradient of the equilibration buffer (A) and 20 mM phosphate buffer (pH 7.5) (B) (from 30 to 100% of B).

Example 6

(76) For the culture supernatant comprising unactivated pro-HGF solution to which active HGFA was not added, Capto adhere purification, CaptoQ purification, UNOsphereS purification, and UF concentration buffer exchange were carried out similarly to Example 5. Non-reductive and reductive SDS-PAGE results of samples obtained in each step shown in FIG. 5 show that the unactivated pro-HGF is also purified in the present purification process.

Example 7

(77) For the active HGF obtained in Example 5, cell proliferation activity in the presence of TGF β -1 was measured. Using mink lung epithelial cell Mv 1 Lu (cell No.: JCRB9128), active HGF was added to cells of which the growth was inhibited in the presence of Transforming Growth Factor β -1 (TGF β -1), and the active HGF proliferation activity thereof based on the antagonistic action on TGF β -1 activity was detected to measure the titer (Journal of Immunological Methods, 258, 1-11, 2001).

(78) In each well of a 96-well plate, 50 μ L of TGF β -1 (4 ng/mL), 50 μ L each of International HGF reference standard (NIBSC code: 96/564) or HGF (0, 4, 8, 16, 32, 64, 128, 256, 512, and 1024 ng/mL), and 100 μ L of mink lung epithelium cell suspension (1×10^5 cells/mL) were added and cultured at 37° C., 5% CO₂ concentration for 3 days, and then viable cells were stained by Cell counting kit (DOJINDO LABORATORIES, Cat No. 343-07623). Using a microplate reader, sigmoid curves were obtained for each of International HGF reference standard and HGF from absorbance at 450 nm (FIG. 6). EC₅₀ of International HGF reference standard and HGF was 13.4 and 15.4 ng/mL, respectively, and HGF obtained with the above production method had activity equivalent to that of the International HGF reference standard.

Sequence Listing

(79) ESAP1601F sequence listing.txt

Claims

1. A method for producing active hepatocyte growth factor activator (HGFA), comprising: a first step of obtaining a culture supernatant comprising inactive hepatocyte growth factor activator (pro-HGFA) by culturing mammalian cells expressing pro-HGFA in a cell culture medium without serum and then removing cells and cell residue from the cell culture medium, wherein said pro-HGFA comprises (i) the amino acid sequence shown in SEQ ID NO: 2, (ii) the amino acid sequence shown in SEQ ID NO:2 which has substitution, deletion, insertion, or addition of 1 to 10 amino acid residues and which is activatable to have HGFA activity, or (iii) an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:2 and which is activatable to have HGFA activity, and a second step of adding an acidic solution to the culture supernatant comprising pro-HGFA obtained in the first step to adjust the culture supernatant to pH 4.0-6.0 and convert pro-HGFA into active HGFA.

2. The production method according to claim 1, wherein said second step further comprises adding sulfated polysaccharides to said culture supernatant.

3. A method for production of active hepatocyte growth factor (HGF), comprising: producing active hepatocyte growth factor activator (HGFA) according to the method of claim 2; and adding said active HGFA to a culture supernatant comprising inactive hepatocyte growth factor (pro-HGF) to convert said pro-HGF into active HGF, wherein said pro-HGF comprises (i) the amino acid sequence shown in SEQ ID NO:1; (ii) the amino acid sequence shown in SEQ ID NO:1 which has

substitution, deletion, insertion, or addition of 1 to 10 amino acid residues and which is activatable to have HGF activity; or (iii) an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 1 and which is activatable to have HGF activity, and wherein said culture supernatant comprising pro-HGF is a culture supernatant obtained by culturing cells expressing pro-HGF in a cell culture medium without serum and then removing cells and cell residue from the cell culture medium.

4. The production method according to claim 3, wherein said cell culture medium for culturing cells expressing pro-HGF is a medium without any animal-derived components.

5. The production method according to claim 1, wherein said second step is performed at a temperature of 15-40° C.

6. A method for production of active hepatocyte growth factor (HGF), comprising: producing active hepatocyte growth factor activator (HGFA) according to the method of claim 5; and adding said active HGFA to a culture supernatant comprising inactive hepatocyte growth factor (pro-HGF) to convert said pro-HGF into active HGF, wherein said pro-HGF comprises (i) the amino acid sequence shown in SEQ ID NO:1; (ii) the amino acid sequence shown in SEQ ID NO:1 which has substitution, deletion, insertion, or addition of 1 to 10 amino acid residues and which is activatable to have HGF activity; or (iii) an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 1 and which is activatable to have HGF activity, and wherein said culture supernatant comprising pro-HGF is a culture supernatant obtained by culturing cells expressing pro-HGF in a cell culture medium without serum and then removing cells and cell residue from the cell culture medium.

7. The production method according to claim 6, wherein said cell culture medium for culturing cells expressing pro-HGF is a medium without any animal-derived components.

8. The production method according to claim 1, wherein said culture supernatant is obtained after a decline in the survival rate of the mammalian cells cultured in the cell culture medium.

9. A method for production of active hepatocyte growth factor (HGF), comprising: producing active hepatocyte growth factor activator (HGFA) according to the method of claim 8; and adding said active HGFA to a culture supernatant comprising inactive hepatocyte growth factor (pro-HGF) to convert said pro-HGF into active HGF, wherein said pro-HGF comprises (i) the amino acid sequence shown in SEQ ID NO:1; (ii) the amino acid sequence shown in SEQ ID NO:1 which has substitution, deletion, insertion, or addition of 1 to 10 amino acid residues and which is activatable to have HGF activity; or (iii) an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 1 and which is activatable to have HGF activity, and wherein said culture supernatant comprising pro-HGF is a culture supernatant obtained by culturing cells expressing pro-HGF in a cell culture medium without serum and then removing cells and cell residue from the cell culture medium.

10. The production method according to claim 9, wherein said cell culture medium for culturing cells expressing pro-HGF is a medium without any animal-derived components.

11. The production method according to claim 1, wherein said mammalian cells are Chinese hamster ovary (CHO) cells.

12. A method for production of active hepatocyte growth factor (HGF), comprising: producing active hepatocyte growth factor activator (HGFA) according to the method of claim 11; and adding said active HGFA to a culture supernatant comprising inactive hepatocyte growth factor (pro-HGF) to convert said pro-HGF into active HGF, wherein said pro-HGF comprises (i) the amino acid sequence shown in SEQ ID NO:1; (ii) the amino acid sequence shown in SEQ ID NO:1 which has substitution, deletion, insertion, or addition of 1 to 10 amino acid residues and which is activatable to have HGF activity; or (iii) an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 1 and which is activatable to have HGF activity, and wherein said culture supernatant comprising pro-HGF is a culture supernatant obtained by culturing cells expressing pro-HGF in a cell culture medium without serum and then removing cells and cell residue from the

cell culture medium.

13. The production method according to claim 12, wherein said cell culture medium for culturing cells expressing pro-HGF is a medium without any animal-derived components.

14. The production method according to claim 1, wherein said method further comprises diluting or concentrating the culture supernatant obtained in the second step.

15. A method for production of active hepatocyte growth factor (HGF), comprising: producing active hepatocyte growth factor activator (HGFA) according to the method of claim 14; and adding said active HGFA to a culture supernatant comprising inactive hepatocyte growth factor (pro-HGF) to convert said pro-HGF into active HGF, wherein said pro-HGF comprises (i) the amino acid sequence shown in SEQ ID NO:1; (ii) the amino acid sequence shown in SEQ ID NO:1 which has substitution, deletion, insertion, or addition of 1 to 10 amino acid residues and which is activatable to have HGF activity; or (iii) an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 1 and which is activatable to have HGF activity, and wherein said culture supernatant comprising pro-HGF is a culture supernatant obtained by culturing cells expressing pro-HGF in a cell culture medium without serum and then removing cells and cell residue from the cell culture medium.

16. The production method according to claim 15, wherein said cell culture medium for culturing cells expressing pro-HGF is a medium without any animal-derived components.

17. A method for production of active hepatocyte growth factor (HGF), comprising: producing active hepatocyte growth factor activator (HGFA) according to the method of claim 1; and adding said active HGFA to a culture supernatant comprising inactive hepatocyte growth factor (pro-HGF) to convert said pro-HGF into active HGF, wherein said pro-HGF comprises (i) the amino acid sequence shown in SEQ ID NO:1; (ii) the amino acid sequence shown in SEQ ID NO:1 which has substitution, deletion, insertion, or addition of 1 to 10 amino acid residues and which is activatable to have HGF activity; or (iii) an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 1 and which is activatable to have HGF activity, and wherein said culture supernatant comprising pro-HGF is a culture supernatant obtained by culturing cells expressing pro-HGF in a cell culture medium without serum and then removing cells and cell residue from the cell culture medium.

18. The production method according to claim 17, wherein said cell culture medium for culturing cells expressing pro-HGF is a medium without any animal-derived components.
